Methotrexat Accord (Methotrexate)

Methotrexate blocks the enzyme dihydrofolate reductase, which stops the formation of tetrahydrofolate. Without tetrahydrofolate, cells cannot synthesize purine nucleotides or thymidylate, leading to impaired DNA synthesis and reduced proliferation of rapidly dividing immune and cancer cells.

The dose is individualized by the prescribing clinician based on the specific indication, patient weight, renal and hepatic function, and treatment goals. No universal dosing schedule is provided; the prescriber sets the appropriate regimen for each patient.

Methotrexat Accord is classified as Pregnancy Category X, meaning it is contraindicated in pregnancy due to a high risk of fetal malformations and loss. It is also not recommended while breastfeeding because it can be excreted in milk and harm the infant.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and any necessary import documentation.

Methotrexat Accord shares the antifolate mechanism with agents such as pemetrexed, but differs in potency, dosing routes and approved indications. Compared with azathioprine, methotrexate generally offers stronger anti‑inflammatory effects for rheumatoid arthritis, while 5‑fluorouracil is used mainly in solid‑tumor chemotherapy rather than autoimmune disease.

Methotrexat Accord should be stored at 2‑8 °C in a refrigerator. Keep the vials in their original packaging, protect them from light, and do not freeze or shake the product. If a temporary temperature excursion occurs, follow the supplier’s stability guidelines before use.

The product is supplied as a sterile injectable solution and is given by a qualified healthcare professional via intra‑arterial, intramuscular or intrathecal injection, depending on the therapeutic indication and the patient’s clinical needs.

The most critical adverse events include severe bone‑marrow suppression leading to pancytopenia, significant hepatotoxicity that can progress to fibrosis or cirrhosis, pulmonary toxicity such as interstitial pneumonitis, and rare but life‑threatening cutaneous reactions like Stevens‑Johnson syndrome.

Methotrexat Accord is contraindicated in pregnant or breastfeeding women, patients with severe renal or hepatic impairment, those with known hypersensitivity to methotrexate or any excipients, and individuals receiving live vaccines without appropriate medical supervision.